M M Macaraig1, M Jalees2, C Lam2, J Burzynski1. 1. New York City Department of Health and Mental Hygiene, New York, New York. 2. New York City Department of Health and Mental Hygiene, New York, New York, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
SETTING: Four New York City (NYC) Health Department tuberculosis (TB) clinics. OBJECTIVE: To assess the effectiveness of preferentially offering two shorter treatment regimens-4 months of daily rifampin (4R) and 3 months of once-weekly isoniazid and rifapentine (3HP)-as an alternative to 9 months of daily isoniazid (9H) for the treatment of latent tuberculous infection (LTBI). DESIGN: Retrospective analysis of patients treated for LTBI from January to June 2015. Poisson regression with robust standard error was used to examine the factors associated with treatment completion. RESULTS: Of the patients on 9H, 49% (27/55) completed treatment compared with 70% (187/269) of patients on 4R (P = 0.003) and 79% (99/125) of patients on 3HP (P < 0.001). When adjusting for age, sex, and TB risk factors, patients on 4R (adjusted risk ratio [aRR] 1.39, 95%CI 1.07-1.81) and 3HP (aRR 1.67, 95%CI 1.27-2.19) were more likely to complete treatment than patients on 9H. Treatment was discontinued due to side effects in 1% (3/269) of patients on 4R, 2% (2/125) of patients on 3HP, and 4% (2/55) of patients on 9H. CONCLUSIONS: Most patients were placed on shorter regimens for LTBI treatment, and higher treatment completion was observed. Encouraging community providers to use shorter regimens for LTBI treatment would reduce the TB disease burden in NYC.
SETTING: Four New York City (NYC) Health Department tuberculosis (TB) clinics. OBJECTIVE: To assess the effectiveness of preferentially offering two shorter treatment regimens-4 months of daily rifampin (4R) and 3 months of once-weekly isoniazid and rifapentine (3HP)-as an alternative to 9 months of daily isoniazid (9H) for the treatment of latent tuberculous infection (LTBI). DESIGN: Retrospective analysis of patients treated for LTBI from January to June 2015. Poisson regression with robust standard error was used to examine the factors associated with treatment completion. RESULTS: Of the patients on 9H, 49% (27/55) completed treatment compared with 70% (187/269) of patients on 4R (P = 0.003) and 79% (99/125) of patients on 3HP (P < 0.001). When adjusting for age, sex, and TB risk factors, patients on 4R (adjusted risk ratio [aRR] 1.39, 95%CI 1.07-1.81) and 3HP (aRR 1.67, 95%CI 1.27-2.19) were more likely to complete treatment than patients on 9H. Treatment was discontinued due to side effects in 1% (3/269) of patients on 4R, 2% (2/125) of patients on 3HP, and 4% (2/55) of patients on 9H. CONCLUSIONS: Most patients were placed on shorter regimens for LTBI treatment, and higher treatment completion was observed. Encouraging community providers to use shorter regimens for LTBI treatment would reduce the TB disease burden in NYC.
Authors: Timothy R Sterling; M Elsa Villarino; Andrey S Borisov; Nong Shang; Fred Gordin; Erin Bliven-Sizemore; Judith Hackman; Carol Dukes Hamilton; Dick Menzies; Amy Kerrigan; Stephen E Weis; Marc Weiner; Diane Wing; Marcus B Conde; Lorna Bozeman; C Robert Horsburgh; Richard E Chaisson Journal: N Engl J Med Date: 2011-12-08 Impact factor: 91.245
Authors: Y Hirsch-Moverman; R Shrestha-Kuwahara; J Bethel; H M Blumberg; T K Venkatappa; C R Horsburgh; P W Colson Journal: Int J Tuberc Lung Dis Date: 2015-01 Impact factor: 2.373
Authors: Courtney M Yuen; Ana K Millones; Jerome T Galea; Daniela Puma; Judith Jimenez; Leonid Lecca; Mercedes C Becerra; Salmaan Keshavjee Journal: BMC Public Health Date: 2021-01-11 Impact factor: 3.295
Authors: Jinsoo Min; Hyung Woo Kim; Helen R Stagg; Molebogeng X Rangaka; Marc Lipman; Ibrahim Abubakar; Yunhee Lee; Jun-Pyo Myong; Hyunsuk Jeong; Sanghyuk Bae; Ah Young Shin; Ji Young Kang; Sung-Soon Lee; Jae Seuk Park; Hyeon Woo Yim; Ju Sang Kim Journal: Front Med (Lausanne) Date: 2022-09-15
Authors: G G Alvarez; D Van Dyk; R Mallick; S Lesperance; P Demaio; S Finn; S Edmunds Potvin; M Patterson; C Pease; K Amaratunga; C Hui; D W Cameron; S Mulpuru; S D Aaron; F Momoli; A Zwerling Journal: Int J Circumpolar Health Date: 2020-12 Impact factor: 1.228